Holen Sie sich die Stockscreener-App
93.35
2.63%
-2.52
Handel nachbörslich:
93.35
Schlusskurs vom Vortag:
$95.87
Offen:
$95.9
24-Stunden-Volumen:
289.58K
Relative Volume:
0.61
Marktkapitalisierung:
$6.22B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-23.94
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
-6.01%
1M Leistung:
+11.96%
6M Leistung:
+39.91%
1J Leistung:
-0.79%
1-Tages-Spanne:
$91.71
$95.90
1-Wochen-Bereich:
$89.02
$99.81
52-Wochen-Spanne:
$55.53
$104.90
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Vergleichen Sie NUVL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
93.35 | 6.97B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
What momentum indicators show for Nuvalent Inc. stockDividend Hike & Momentum Based Trading Ideas - newser.com
How Nuvalent Inc. stock trades during market volatilityGold Moves & High Accuracy Investment Signals - newser.com
Can Nuvalent Inc. stock maintain growth trajectory2025 Price Action Summary & Weekly High Return Forecasts - newser.com
Nuvalent’s Zidesamtinib Study: A Potential Game-Changer in Cancer Treatment - MSN
Why Nuvalent Inc. stock attracts high net worth investors2025 Sector Review & Reliable Price Breakout Signals - fcp.pa.gov.br
Will Nuvalent Inc. bounce back from current supportWeekly Trade Analysis & Accurate Buy Signal Alerts - newser.com
Why Nuvalent Inc. stock remains resilientQuarterly Profit Report & Free Weekly Watchlist of Top Performers - newser.com
Will Nuvalent Inc. stock rally after Fed decisionsGlobal Markets & Daily Chart Pattern Signal Reports - newser.com
Using economic indicators to assess Nuvalent Inc. potential2025 Fundamental Recap & Smart Allocation Stock Tips - newser.com
Why Nuvalent Inc. stock is trending among retail tradersJuly 2025 Trends & Long-Term Capital Growth Strategies - newser.com
Can volume confirm reversal in Nuvalent Inc.Trade Volume Summary & Risk Controlled Stock Pick Alerts - newser.com
Custom strategy builders for tracking Nuvalent Inc.Dip Buying & Daily Market Momentum Tracking - newser.com
What data driven models say about Nuvalent Inc.’s futureFed Meeting & Daily Chart Pattern Signal Reports - newser.com
Is Nuvalent Inc. stock a bargain at current levelsGold Moves & Long-Term Growth Portfolio Plans - newser.com
Nuvalent to present zidesamtinib patient data at lung cancer conference By Investing.com - Investing.com Nigeria
Why analysts remain bullish on Nuvalent Inc. stockWeekly Investment Report & Verified Stock Trade Ideas - newser.com
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer - Lelezard
Statistical indicators supporting Nuvalent Inc.’s strengthMarket Activity Summary & Trade Opportunity Analysis - newser.com
Nuvalent: Interesting Product, But Aggressive Valuation (NASDAQ:NUVL) - Seeking Alpha
Nuvalent to present zidesamtinib patient data at lung cancer conference - Investing.com
Nuvalent unveils patient outcomes data at key cancer conference - Traders Union
Nuvalent (NASDAQ: NUVL) to present ARROS-1 PRO and pivotal efficacy/safety at IASLC ASCO - Stock Titan
Published on: 2025-11-04 11:51:01 - newser.com
How risky is Nuvalent Inc. stock now2025 Volume Leaders & Verified Momentum Stock Watchlist - newser.com
Can Nuvalent Inc. stock outperform in 2025 bull market2025 Retail Activity & Reliable Trade Execution Plans - newser.com
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.44%
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):